Vaccines for HSV-2
US9895435B2 · kind B2 · utility
1Cited by
189References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 16, 2013 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | May 16, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16634
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.